Skip to main content
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc — Investor Relations & Filings

Ticker · SNDX ISIN · US87164F1057 LEI · 529900OF94TRHKZVBS87 US Manufacturing
Open in API
Filings indexed 618 across all filing types
Latest filing 2025-05-05 Regulatory Filings
Country US United States of America
Listing US SNDX

About Syndax Pharmaceuticals Inc

https://syndax.com/

Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes therapies for various cancers. The company focuses on developing first-in-class and best-in-class treatments for areas with significant unmet medical needs, such as acute leukemias and chronic Graft-versus-Host Disease (GVHD). Its pipeline targets a range of hematological malignancies and solid tumors, utilizing approaches in epigenetics and immunomodulation to create transformative therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing its financial results for the quarter and year ended March 31, 2025, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 3877 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and states that a report or press release is attached or furnished, it should be classified as a Regulatory Filing (RNS) rather than the actual Earnings Release (ER) or Interim Report (IR). Therefore, this document is best classified as a Regulatory Filing (RNS).
2025-05-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-17 English
ARS
Annual Report
2025-04-01 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is marked as 'Definitive Additional Materials' related to the proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (1055 characters) and does not contain financial data or report content but is related to shareholder voting information. Therefore, it fits the Proxy Solicitation & Information Statement category (PSI).
2025-04-01 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-01 English
4
Director's Dealing
2025-03-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.